Appili Therapeutics Inc. (TSX: APLI)
Canada
· Delayed Price · Currency is CAD 0.0400
0.00 (0.00%)
Jul 2, 2024, 2:20 PM EDT
Appili Therapeutics Revenue
In the fiscal year ending March 31, 2024, Appili Therapeutics had annual revenue of 827.41K CAD with 147.60% growth. Revenue in the quarter ending March 31, 2024 was 11.70K CAD, a -96.50% decrease year-over-year.
Revenue
827.41K
Revenue Growth
+147.60%
P/S Ratio
5.86
Revenue / Employee
103,426
Employees
8
Market Cap
4.85M CAD
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2024 | 827.41K | 493.23K | 147.60% |
| Mar 31, 2023 | 334.18K | -1.06M | -75.97% |
| Mar 31, 2022 | 1.39M | - | - |
| Mar 31, 2021 | 0 | - | - |
| Mar 31, 2020 | 199.11K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Bausch + Lomb Corporation | 5.91B |
| Curaleaf Holdings, Inc. | 1.84B |
| Bausch Health Companies Inc. | 12.26B |
| Tilray Brands, Inc. | 1.02B |
| WELL Health Technologies Corp. | 838.19M |
| Sienna Senior Living Inc. | 824.26M |
| Canopy Growth Corporation | 329.61M |
| Extendicare Inc. | 1.35B |
Appili Therapeutics News
- 18 hours ago - Appili Therapeutics Announces Amendment to Arrangement Agreement and Increase to Bridge Loan - GlobeNewsWire
- 7 days ago - Appili Therapeutics Reports Fiscal Year 2024 Financial and Operational Results - GlobeNewsWire
- 2 months ago - Appili Therapeutics Announces Additional Bridge Loan from Bloom Burton & Co. - GlobeNewsWire
- 3 months ago - Why Stryve Foods Shares Are Trading Lower By Around 25%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session - Benzinga
- 3 months ago - Aditxt signs agreement to acquire Appili Therapeutics - Seeking Alpha
- 3 months ago - Aditxt Signs a Definitive Agreement to Acquire Appili Therapeutics Inc., Developer of a Biodefense Vaccine Funded by the U.S. Department of Defense (DoD) - Business Wire
- 3 months ago - Appili Therapeutics Signs Definitive Agreement to be Acquired by Aditxt, Inc. - GlobeNewsWire
- 4 months ago - Researchers Publish Manuscript on the Prevention and Emergency Response to Tularemia Outbreaks - GlobeNewsWire